EarningsQ2 2026 Earnings Report
MX:NEO Q2 2026 EPS Results
Actual EPS$0.91
Consensus EPS$0.62
Beat/MissBeat by +$0.29
One Year Ago EPS$0.55
MX:NEO Q2 2026 Revenue Results
Actual Revenue$3.67B
Expected Revenue$3.58B
Beat/MissBeat by +$86.00M
YoY Revenue Growth+11.21%
Earnings Announcement Details
QuarterQ2 2026
Date07/28/2026
TimeAfter Close
Conference CallTuesday, July 28, 2026
MX:NEO Upcoming Earnings
NeoGenomics's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:NEO Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.Company Guidance
Commercial Execution and Organizational Scaling
Reorganized commercial team into two ecosystems (oncology and pathology); on track to exceed 160 commercial reps in Q3; Net Promoter Score in the high 70s across pathology and oncology indicating strong customer experience.
Product and Pipeline Progress
PanTracer Family and RaDaR ST continuing commercialization with early commercial traction; next-gen whole genome sequencing MRD assay on track (data expected 2027, potential clinical launch 2029); launched PTEN IHC companion diagnostic for prostate cancer.
Balance Sheet Actions and Liquidity
Raised $316M via convertible senior notes (2032) and retired $276M of 2028 notes; repurchased $25M of common stock; ended quarter with $145.5M cash and generated ~$20M operating cash while investing $8M in capex.
Revenue Outperformance and Guidance Raise
Total revenue of $201.7M, up 11% year-over-year and ~ $4M ahead of prior guidance; company raised 2026 revenue guidance to $802M–$806M (from $797M–$803M).
Strong Clinical Growth
Clinical revenue grew 14% YoY, driven by a 12% increase in average unit price (AUP) and volumes up 2%; clinical growth outpaced total company growth and remains core to the business.
NGS Momentum
NGS revenue grew 26% YoY, comprising roughly one-third of clinical revenue; larger panels grew >20% and NGS guidance was raised to mid-20% growth for the full year.
Margin Expansion and Profitability Progress
Adjusted gross margin expanded ~260 basis points YoY to 48.1%; adjusted gross profit increased 18% to $96.9M; adjusted EBITDA was $14.4M, up 36% YoY, and full-year adjusted EBITDA guidance was raised to $56M–$58M.
Lab of the Future and Operational Efficiencies
Lab of the Future initiatives (automation, digital pathology, instrument upgrades, NeoLIMS, procurement, footprint optimization) delivered efficiencies this quarter, including NovaSeq X migration for PanTracer LBx to improve throughput, TAT and future per-test cost.
MX:NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed